Stephenson Harwood LLP has advised Oxford Biomedica on the deal. Oxford Biomedica, the gene and cell therapy company, on its new three year Master Services &...
Oxford Biomedica’s Agreement With AstraZeneca UK Ltd
AM-Pharma’s €245 Million License Agreement With Kyowa Kirin
Stephenson Harwood LLP has advised AM-Pharma on the deal. AM-Pharma signed a €245 million exclusive license agreement deal with Kyowa Kirin, for the development and commercialisation...